homepage-top-section

Cosentyx is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis

Tilos Therapeutics is involved in the development of therapeutics, which targets the latent TGFβ complex to treat cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine supposed

In January 2017, Acucela had received orphan drug designation from the US Food and Drug Administration (FDA) for emixustat to treat Stargardt disease. Stargardt disease is a rare

The approval for ZYNTEGLO is for the treatment of TDT in patients 12 years and older who do not have a β0/β0 genotype and for those who are

Revlimid plus rituximab is claimed to be the FDA-approved combination treatment regimen for patients with these indolent forms of non-Hodgkin’s lymphoma (NHL), which does not include chemotherapy. Celgene

Neuraxpharm has entered into an exclusive licensing agreement with the probiotics company Bened Biomedical, under which Neuraxpharm secured exclusive rights to market its first probiotic lactobacillus plantarum PS128

The phase 3 CheckMate -498 trial assessing Opdivo plus radiation against temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not achieve

The trial results demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence monotherapy compared against a combination regimen of rituximab plus physician’s choice of idelalisib

Under an exclusive worldwide license agreement, Fulcrum will develop and commercialize losmapimod, a potential disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is planning to advance losmapimod into